Patents by Inventor Felix Bachmann

Felix Bachmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8802858
    Abstract: A compound of formula II in which Z is C or N and the Z ring is optionally further substituted; R1 is H, lower alkylcarbonyl, hydroxy-lower alkyl or cyano-lower alkyl; and R2 is a group selected from (b), (c), and (d):
    Type: Grant
    Filed: July 26, 2010
    Date of Patent: August 12, 2014
    Assignee: Basilea Pharmaceutica AG
    Inventors: Jens Pohlmann, Felix Bachmann
  • Publication number: 20140080872
    Abstract: Use of phospho-Akt as a biomarker for predicting the response, such as resistance, to a compound, wherein phospho-Akt is Akt that has been phosphorylated on one or more residues, with the proviso that for Akt1, Akt2, and Akt3 the designation phospho-Akt is used to indicate phosphorylation at a site other than T308, T309 or T305 respectively, wherein the compound is a compound of general formula (I) wherein R represents phenyl, thienyl or pyridinyl wherein phenyl is optionally substituted by one or two substituents independently selected from alkyl, halo-lower alkyl, hydroxy-lower alkyl, lower alkoxy-lower alkyl, acyloxy-lower alkyl, phenyl, hydroxy, lower alkoxy, hydroxy-lower alkoxy, lower alkoxy-lower alkoxy, phenyl-lower alkoxy, lower alkylcarbonyloxy, amino, monoalkylamino, dialkylamino, lower alkoxycarbonylamino, lower alkylcarbonylamino, substituted amino wherein the two substituents on nitrogen form together with the nitrogen heterocyclyl, lower alkylcarbonyl, carboxy, lower alkoxycarbonyl, cyano, halo
    Type: Application
    Filed: March 28, 2012
    Publication date: March 20, 2014
    Inventors: Heidi Alexandra Lane, Felix Bachmann
  • Publication number: 20140045897
    Abstract: Use of BUBR1 as a biomarker for predicting the response to a compound, preferably resistance of a disease such as cancer in a subject, wherein the compound is a furazanobenzimidazole compound of general formula (I).
    Type: Application
    Filed: January 19, 2012
    Publication date: February 13, 2014
    Inventors: Heidi Alexandra Lane, Felix Bachmann, Madlaina Breuleux, Michael Boutros, Daniel Gilbert, Xian Zhang
  • Publication number: 20140024686
    Abstract: Use of glu-tubulin as a biomarker for predicting the response to a compound, preferably resistance of a disease such as cancer in a subject to said compound, wherein the compound is a furazanobenzimidazole compound of general formula (I).
    Type: Application
    Filed: January 19, 2012
    Publication date: January 23, 2014
    Applicant: Basilea Pharmaceutica AG
    Inventors: Heidi Alexandra Lane, Felix Bachmann
  • Publication number: 20140005237
    Abstract: Use of acetylated tubulin as a biomarker for predicting the response to a compound, preferably resistance of a disease such as cancer in a subject to said compound, wherein the compound is a furazanobenzimidazoles compound of general formula (I).
    Type: Application
    Filed: February 21, 2012
    Publication date: January 2, 2014
    Inventors: Heidi Alexandra Lane, Felix Bachmann
  • Publication number: 20130345263
    Abstract: Use of stathmin as a biomarker for predicting the response, such as resistance, to a compound, wherein the compound is a furazanobenzimidazole compound of general formula (I).
    Type: Application
    Filed: January 19, 2012
    Publication date: December 26, 2013
    Applicant: Basilea Pharmaceutica AG
    Inventors: Heidi Alexandra Lane, Felix Bachmann
  • Patent number: 8486996
    Abstract: The invention relates to novel substituted 2-(phenyl-, pyridyl- or pyrimidyl-carbonyl)-furanes and -thiophenes and related phenoxy/phenylthio-acetophenones and corresponding heterocyclic compounds, processes for the preparation thereof, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of neoplastic diseases and autoimmune diseases, and a method for the treatment of such a diseases.
    Type: Grant
    Filed: May 12, 2006
    Date of Patent: July 16, 2013
    Assignee: Basilea Pharmaceutica AG
    Inventors: Martin Eberle, Felix Bachmann, Alessandro Strebel, Subho Roy, Goutam Saha, Subir Kumar Sadhukhan, Rohit Saxena, Sudhir Srivastava
  • Publication number: 20120264792
    Abstract: A compound of formula (II) wherein represents a divalent benzene residue which is unsubstituted or substituted by one or two additional substituents independently selected from lower alkyl, halo-lower alkyl, hydroxy-lower alkyl, lower alkoxy-lower alkyl, acyloxy-lower alkyl, phenyl, hydroxy, lower alkoxy, hydroxy-lower alkoxy, lower alkoxy-lower alkoxy, phenyl-lower alkoxy, lower alkylcarbonyloxy, amino, mono(lower alkyl)amino, di(lower alkyl)amino, mono(lower alkenyl)amino, di(lower alkenyl)amino, lower alkoxycarbonylamino, lower alkylcarbonylamino, substituted amino wherein the two substituents on nitrogen form together with the nitrogen heterocyclyl, lower alkylcarbonyl, carboxy, lower alkoxycarbonyl, cyano, halogen, and nitro; or wherein two adjacent substituents can be methylenedioxy; or a divalent pyridine residue (Z=N) which is unsubstituted or substituted additionally by lower alkyl, lower alkoxy, lower alkoxy-lower alkoxy, amino, optionally substituted by one or two substituents selected fro
    Type: Application
    Filed: July 26, 2010
    Publication date: October 18, 2012
    Inventors: Jens Pohlmann, Felix Bachmann
  • Patent number: 8288421
    Abstract: The invention relates to novel substituted 3-phenylamino-5-(3-aminophenyl)pyridines and corresponding pyrazines of formula (I), wherein A is CH or N, R1 represents C(?O)R9, S(?O)2R10, P(?O)(OR11)2, optionally substituted phenyl or optionally substituted heteroaryl, and the other substituents have the meaning described in the specification, processes for the preparation thereof, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of neoplastic diseases and autoimmune diseases, and a method for the treatment of such a diseases.
    Type: Grant
    Filed: September 5, 2005
    Date of Patent: October 16, 2012
    Assignee: Basilea Pharmaceutica AG
    Inventors: Martin Eberle, Felix Bachmann, Alessandro Strebel, Subho Roy, Goutam Saha, Godhuli Nandi
  • Patent number: 7951957
    Abstract: The invention relates to compounds of formula (I) wherein R represents aryl or heteroaryl, X is a bond, a carbonyl group, a derivative of a carbonyl group, an ethylene group or an ethylenecarbonyl group, R1 is optionally substituted amino or hydroxy, and the substituents R2 to R6 have the meanings given in the specification, to methods of synthesis of such compounds, to pharmaceutical compositions containing compounds of formula (I), to intermediates, to the use of a compounds of formula (I) as a medicament and for the preparation of a pharmaceutical composition for the treatment of neoplastic and autoimmune diseases, and to methods of treatment of neoplastic and autoimmune diseases using such compounds of formula (I) or of pharmaceutical compositions containing same.
    Type: Grant
    Filed: July 16, 2008
    Date of Patent: May 31, 2011
    Assignee: Basilea Pharmaceutica AG
    Inventors: Martin Eberle, Felix Bachmann, Alessandro Strebel, Subho Roy, Sudhir Srivastava, Goutam Saha
  • Patent number: 7612064
    Abstract: The invention relates to compounds of formula (I) wherein R1 represents aryl, aralkyl or heteroaryl, R2 is aryl or heteroaryl and R3 is aryl, heteroaryl or optionally substituted aminomethyl, to methods of synthesis of such compounds, to pharmaceutical compositions containing compounds of formula (I), to the use of a compounds of formula (I) for the preparation of a pharmaceutical composition for the treatment of neoplastic and autoimmune diseases, and to methods of treatment of neoplastic and autoimmune diseases using compounds of formula (I) or of pharmaceutical compositions containing same.
    Type: Grant
    Filed: May 24, 2004
    Date of Patent: November 3, 2009
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Martin Eberle, Philipp Ermert, Daniel Obrecht, Frank Lach, Anatol Luther, Felix Bachmann, Allessandro Strebel
  • Publication number: 20080287681
    Abstract: The invention relates to compounds of formula (I) wherein R represents aryl or heteroaryl, X is a bond, a carbonyl group, a derivative of a carbonyl group, an ethylene group or an ethylenecarbonyl group, R1 is optionally substituted amino or hydroxy, and the substituents R2 to R6 have the meanings given in the specification, to methods of synthesis of such compounds, to pharmaceutical compositions containing compounds of formula (I), to intermediates, to the use of a compounds of formula (I) as a medicament and for the preparation of a pharmaceutical composition for the treatment of neoplastic and autoimmune diseases, and to methods of treatment of neoplastic and autoimmune diseases using such compounds of formula (I) or of pharmaceutical compositions containing same.
    Type: Application
    Filed: July 16, 2008
    Publication date: November 20, 2008
    Inventors: Martin Eberle, Felix Bachmann, Alessandro Strebel, Subho Roy, Sudhir Srivastava, Goutam Saha
  • Publication number: 20080221171
    Abstract: The invention relates to novel substituted 3-phenylamino-5-(3-aminophenyl)pyridines and corresponding pyrazines of formula (I), wherein A is CH, C-lower alkyl or N, R1 represents C(?O)R9, S(?O)2R10, P(?O)(OR11)2, optionally substituted phenyl or optionally substituted heteroaryl, and the other substituents have the meaning described in the specification, processes for the preparation thereof, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of neoplastic diseases and autoimmune diseases, and a method for the treatment of such diseases.
    Type: Application
    Filed: September 5, 2005
    Publication date: September 11, 2008
    Applicant: BASILEA PHARMACEUTICA AG
    Inventors: Martin Eberle, Felix Bachmann, Alessandro Strebel, Subho Roy, Goutam Saha, Godhuli Nandi
  • Patent number: 7423157
    Abstract: The invention relates to compounds of formula (I) wherein R represents aryl or heteroaryl, X is a bond, a carbonyl group, a derivative of a carbonyl group, an ethylene group or an ethylenecarbonyl group, R1 is optionally substituted amino or hydroxy, and the substituents R2 to R6 have the meanings given in the specification, to methods of synthesis of such compounds, to pharmaceutical compositions containing compounds of formula (I), to intermediates, to the use of a compounds of formula (I) as a medicament and for the preparation of a pharmaceutical composition for the treatment of neoplastic and autoimmune diseases, and to methods of treatment of neoplastic and autoimmune diseases using such compounds of formula (I) or of pharmaceutical compositions containing same.
    Type: Grant
    Filed: August 9, 2006
    Date of Patent: September 9, 2008
    Assignee: Basilea Pharmaceutica AG
    Inventors: Martin Eberle, Felix Bachmann, Alessandro Strebel, Subho Roy, Sudhir Srivastava, Goutam Saha
  • Patent number: 7385061
    Abstract: The invention relates to compounds of formula (I) wherein R represents aryl or heteroaryl, X is oxygen, a carbonyl group, an oxime derivative of a carbonyl group or an ?,?-unsaturated carbonyl group, and the substituents R1 to R6 have the meanings given in the specification, for use as medicaments, to novel compounds of formula (I), to methods of synthesis of such compounds, to pharmaceutical compositions containing compounds of formula (I), to the use of a compounds of formula (I) for the preparation of a pharmaceutical composition for the treatment of neoplastic and autoimmune diseases, and to methods of treatment of neoplastic and autoimmune diseases using such compounds of formula (I) or of pharmaceutical compositions containing same
    Type: Grant
    Filed: May 19, 2004
    Date of Patent: June 10, 2008
    Assignee: Basilea Pharmaceutica AG
    Inventors: Martin Eberle, Felix Bachmann, Alessandro Strebel, Subho Roy, Sudhir Srivastava, Goutam Saha
  • Publication number: 20070167505
    Abstract: The invention relates to compounds of formula (I) wherein R represents aryl or heteroaryl, X is a bond, a carbonyl group, a derivative of a carbonyl group, an ethylene group or an ethylenecarbonyl group, R1 is optionally substituted amino or hydroxy, and the substituents R2 to R6 have the meanings given in the specification, to methods of synthesis of such compounds, to pharmaceutical compositions containing compounds of formula (I), to intermediates, to the use of a compounds of formula (I) as a medicament and for the preparation of a pharmaceutical composition for the treatment of neoplastic and autoimmune diseases, and to methods of treatment of neoplastic and autoimmune diseases using such compounds of formula (I) or of pharmaceutical compositions containing same.
    Type: Application
    Filed: February 10, 2005
    Publication date: July 19, 2007
    Inventors: Martin Eberle, Felix Bachmann, Alessandro Strebel, Subho Roy, Sudhir Srivastava, Goutam Saha
  • Publication number: 20070066670
    Abstract: The invention relates to compounds of formula (I) wherein R represents aryl or heteroaryl, X is a bond, a carbonyl group, a derivative of a carbonyl group, an ethylene group or an ethylenecarbonyl group, R1 is optionally substituted amino or hydroxy, and the substituents R2 to R6 have the meanings given in the specification, to methods of synthesis of such compounds, to pharmaceutical compositions containing compounds of formula (I), to intermediates, to the use of a compounds of formula (I) as a medicament and for the preparation of a pharmaceutical composition for the treatment of neoplastic and autoimmune diseases, and to methods of treatment of neoplastic and autoimmune diseases using such compounds of formula (I) or of pharmaceutical compositions containing same.
    Type: Application
    Filed: August 9, 2006
    Publication date: March 22, 2007
    Inventors: Martin Eberle, Felix Bachmann, Alessandro Strebel, Subho Roy, Sudhir Srivastava, Goutam Saha
  • Publication number: 20070060570
    Abstract: The invention relates to compounds of formula (I) wherein R1 represents aryl, aralkyl or heteroaryl, R2 is aryl or heteroaryl and R3 is aryl, heteroaryl or optionally substituted aminomethyl, to methods of synthesis of such compounds, to pharmaceutical compositions containing compounds of formula (I), to the use of a compounds of formula (I) for the preparation of a pharmaceutical composition for the treatment of neoplastic and autoimmune diseases, and to methods of treatment of neoplastic and autoimmune diseases using compounds of formula (I) or of pharmaceutical compositions containing same.
    Type: Application
    Filed: May 24, 2004
    Publication date: March 15, 2007
    Applicant: Taleda Pharmaceutical Company Limited
    Inventors: Martin Eberle, Daniel Obrecht, Philipp Ermert, Franck Lach, Anatol Luther, Felix Bachmann, Alessandro Strebel
  • Publication number: 20070043061
    Abstract: The invention relates to compounds of formula (I) wherein R represents aryl or heteroaryl, X is oxygen, a carbonyl group, an oxime derivative of a carbonyl group or an ?,?-unsaturated carbonyl group, and the substituents R1 to R6 have the meanings given in the specification, for use as medicaments, to novel compounds of formula (I), to methods of synthesis of such compounds, to pharmaceutical compositions containing compounds of formula (I), to the use of a compounds of formula (I) for the preparation of a pharmaceutical composition for the treatment of neoplastic and autoimmune diseases, and to methods of treatment of neoplastic and autoimmune diseases using such compounds of formula (I) or of pharmaceutical compositions containing same.
    Type: Application
    Filed: May 19, 2004
    Publication date: February 22, 2007
    Inventors: Martin Eberle, Felix Bachmann, Alessandro Strebel, Subho Roy, Sudhir Srivastava, Goutham Saha
  • Patent number: RE42890
    Abstract: The invention relates to compounds of formula (I) wherein R represents aryl or heteroaryl, X is oxygen, a carbonyl group, an oxime derivative of a carbonyl group or an ?,?-unsaturated carbonyl group, and the substituents R1 to R6 have the meanings given in the specification, for use as medicaments, to novel compounds of formula (I), to methods of synthesis of such compounds, to pharmaceutical compositions containing compounds of formula (I), to the use of a compounds of formula (I) for the preparation of a pharmaceutical composition for the treatment of neoplastic and autoimmune diseases, and to methods of treatment of neoplastic and autoimmune diseases using such compounds of formula (I) or of pharmaceutical compositions containing same
    Type: Grant
    Filed: May 19, 2004
    Date of Patent: November 1, 2011
    Assignee: Basilea Pharmaceutica AG
    Inventors: Martin Eberle, Felix Bachmann, Alessandro Strebel, Subho Roy, Sudhir Srivastava, Goutam Saha